Deuterated 2-aromatic heterocyclic-3-oxo-2,3-dihydropyridazine-4-carboxamide inhibitors, methods for producing the same, and applications

Deuterated 3-oxo-2,3-dihydropyridazine-4-carboxamide compounds provide selective AhR inhibition, addressing the need for effective cancer treatment by targeting AhR-mediated immunosuppression and enhancing immunotherapy.

JP7869210B2Active Publication Date: 2026-06-02SUZHOU ZELGEN BIOPHARML +1

Patent Information

Authority / Receiving Office
JP · JP
Patent Type
Patents
Current Assignee / Owner
SUZHOU ZELGEN BIOPHARML
Filing Date
2021-11-29
Publication Date
2026-06-02

AI Technical Summary

Technical Problem

There is a need for highly selective and active Aryl Hydrocarbon Receptor (AhR) inhibitors to treat diseases such as cancer mediated by AhR abnormalities while minimizing off-target effects.

Method used

Development of deuterated 3-oxo-2,3-dihydropyridazine-4-carboxamide compounds with specific structural formulas and their derivatives, including stereoisomers, crystal forms, pharmaceutically acceptable salts, hydrates, and solvates, which exhibit selective inhibitory effects on AhR.

Benefits of technology

The compounds effectively inhibit AhR, potentially treating tumors and other diseases by reducing immunosuppression and enhancing immunotherapy efficacy, with minimal off-target effects.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure 0007869210000043
    Figure 0007869210000043
  • Figure 0007869210000001
    Figure 0007869210000001
  • Figure 0007869210000002
    Figure 0007869210000002
Patent Text Reader

Abstract

The present invention relates to a deuterated 3-oxo-2,3-dihydropyridazine-4-carboxamide inhibitor, its preparation method, and application. Specifically, the compound of the present invention has a structure represented by formula (I). The present invention further discloses a preparation method of the compound and its use as an AhR inhibitor. The compound of the present invention has excellent selectivity for inhibiting AhR, as well as superior pharmacodynamic and pharmacokinetic properties, and reduced toxicity and side effects. [Formula 1] JPEG2023551019000050.jpg4162
Need to check novelty before this filing date? Find Prior Art